National Biopharma Mission aims to accelerate the development of cost effective, safe and efficacious biosimilars of monoclonal antibodies and other therapeutic proteins that have high market scope, addresses India’s disease burden and are feasible for development based on patent expiry of original biotherapeutic (2015-2020 US/EU) or not patent protected in India. The biosimilars supported under this call are for diseases like cancer, Type I and Type II diabetes, rheumatoid arthritis and age-related wet AMD.
|
Therapeutic Area/ Name of Product |
Name of grantee |
Development Phase Supported |
Environmental and Health Risk Management Plan (EHRMP) |
|
Diabetes/ Insulin Glargine |
Vitane Biologics Pvt. Ltd. |
Preclinical |
Click Here |
| Emergency situations/ Human Serum Albumin |
BIBCOL National Institute of Immunology |
Preclinical | |
| Cancer/ Trastuzumab | Serum Institute of India Pvt. Ltd. | Preclinical | Click Here |
| Liraglutide | Levim Biotech LLP | Process scale upto 200 L scale and Phase III Clinical Trial | Click Here |
| Wet-AMD/Ranibizumab | National Chemical laboratory (NCL), Pune | Process development and Analytical method development | Click Here |
| Wet-AMD/Ranibizumab | Indian institute of Technology (IIT), Delhi | Process development and Analytical method development | Click Here |
| Diabetes/Insulin Glargine | Stelis Biopharma Pvt Ltd | GMP manufacturing & clinical development | Click Here |
| rHU Biosimilar Insulin Lispro | National Chemical laboratory (NCL), Pune and Indian institute of Technology (IIT), Delhi | Preclinical | Click Here |
| Psoriatic Arthritis/Ustekinumab | Serum Institute of India Pvt Ltd | Preclinical to Clinical | Click Here |
| Lung infections caused by RSV/Palivizumab | Serum Institute of India Pvt Ltd | Preclinical to Clinical | Click Here |
| Wet-AMD/Aflibercept | Lupin Ltd | Preclinical to Clinical | Click Here |
| Recombinant Human Albumin | Lazuline Biotech Private Limited, Hyderabad | Process development and commercialization | Click Here |